Phase II trial of echinomycin in advanced soft tissue sarcomas |
| |
| Authors: | Sarah A. Taylor Barbara Metch Stanley P. Balcerzak Karl H. Hanson |
| |
| Affiliation: | (1) University of Kansas Medical Center, Kansas City, KS, USA;(2) Southwest Oncology Group Statistical Center, Seattle, WA, USA;(3) Ohio State University Health Center, Columbus, OH, USA;(4) Midwest Community Clinical Oncology Program, Kansas City, MO, USA |
| |
| Abstract: | Summary Thirty-four patients with advanced soft tissue sarcomas were entered in a phase II trial of echinomycin. Patients received 1.2 mg/m2 intravenously (i.v.) weekly times four followed by a two week rest period. There were no objective responses. Dose limiting toxicity was gastrointestinal. Echinomycin given on this weekly schedule is inactive in treating previously treated patients with advanced soft tissue sarcomas.Southwest Oncology Group (SWOG-8505), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229-6197, USA |
| |
| Keywords: | phase II trial soft tissue sarcoma echinomycin |
| 本文献已被 SpringerLink 等数据库收录！ |
|
